Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Surg Oncol ; 2024: 1910430, 2024.
Article in English | MEDLINE | ID: mdl-38910955

ABSTRACT

Intra-abdominal desmoid tumors are a rare and complex clinical problem. These tumors are locally invasive, and surgical ablation represents the mainstay of treatment. When localized at the root of the mesentery, their resection may require extensive excision of the intestine resulting in intestinal failure and life-long total parenteral nutrition. Intestinal transplantation, either autotransplantation or allotransplantation, has been used as a viable option to treat this group of patients. Herein, we describe a series of 4 patients with unresectable intra-abdominal desmoid tumor who underwent cadaveric isolated intestinal and ascending colon transplantation.


Subject(s)
Colon , Humans , Male , Female , Adult , Colon/transplantation , Colon/surgery , Middle Aged , Intestines/transplantation , Intestines/surgery
2.
Hum Immunol ; 85(3): 110787, 2024 May.
Article in English | MEDLINE | ID: mdl-38480040

ABSTRACT

INTRODUCTION: Intestinal transplantation poses a unique challenge in the field of solid organ transplantation. The combination of tacrolimus and prednisone stands as the foundational cornerstone of maintenance immunosuppression in the field of intestinal transplantation. This case series aims to describe 1-year clinical outcomes of 5 intestinal transplant recipients who received a novel immunosuppression regimen consisting of monthly basiliximab, sublingual tacrolimus, and prednisone. METHODS: A retrospective analysis of patients who underwent intestinal transplantation in our center between January 01, 2020, and January 31, 2022, was conducted. Each recipient was followed for at least 1-year post-transplant. Recipient baseline demographics, clinical characteristics, and follow-up data were obtained from the electronic health records. Data collection included recipient demographics (age, sex, race/ethnicity, BMI), cause of intestinal failure, immunological data, infectiology data and treatment information. RESULTS: A total of five patients underwent intestinal transplantation, of which two males (40 %) and three females (60 %), with a median age of 20.1 years (17.4-28.8). The median (IQR) tacrolimus trough by month 1 was 10.4 (8.4-13.2) ng/mL. Subsequently, the median (IQR) tacrolimus troughs at specified periods are as follows, respectively: month 3: 10.2 (8.2-13.2) ng/mL; month 6: 8.4 (7.6-9.6) ng/mL; and month 12: 8.8 (6.2-9.8) ng/mL. Three patients (60.0 %) had biopsy proven rejection, but all of them had resolution after the optimization of immunosuppression. All patients were alive and had a functioning intestinal allograft at 1-year. CONCLUSION: The combination of monthly basiliximab, sublingual tacrolimus, and prednisone is an effective novel maintenance immunosuppression in intestinal transplantation. A larger and more extended study duration would be necessary to thoroughly assess the safety and sustained benefits of the novel maintenance immunosuppression regimen.


Subject(s)
Basiliximab , Graft Rejection , Immunosuppressive Agents , Prednisone , Tacrolimus , Humans , Tacrolimus/administration & dosage , Tacrolimus/therapeutic use , Basiliximab/administration & dosage , Basiliximab/therapeutic use , Male , Female , Prednisone/therapeutic use , Prednisone/administration & dosage , Adult , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use , Retrospective Studies , Graft Rejection/prevention & control , Graft Rejection/immunology , Young Adult , Adolescent , Treatment Outcome , Intestines/transplantation , Intestines/immunology , Graft Survival/drug effects , Transplant Recipients , Organ Transplantation , Drug Therapy, Combination
3.
Am J Transplant ; 24(6): 1035-1045, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38158189

ABSTRACT

The diabetic population is witnessing a rise in obesity rates, creating specific hurdles for individuals seeking pancreas transplantation because they are frequently disqualified due to their elevated body weight. Introducing a robotic-assisted approach to transplantation has been proven to yield improved outcomes, particularly in patients with obesity. A retrospective analysis was conducted between January 2015 and September 2023. The study included a total of 140 patients, with 16 receiving robotic-assisted simultaneous pancreas-kidney transplantation (RSPK) and 124 undergoing open approach simultaneous pancreas-kidney transplantation (OSPK) during the study period. The median age was 45 (36.8-52.7) and 44.5 years (36.8-51.8) (RSPK vs OSPK, P = .487). There were no significant differences in demographics except body mass index (RSPK vs OSPK, 34.9 vs 28.1, P < .001) and a higher percentage of patients with high cardiac risk in the RSPK group. The robotic approach has a lengthier overall operative time and warm ischemia time. Surgical and nonsurgical complications at 30-days and 1-year grafts and patient survival (93.8% vs 96.8%, RSPK vs OSPK, P = .521) were similar. Our findings suggest that employing robotic assistance in simultaneous pancreas-kidney transplantation is safe. Wider adoption and utilization of this technique could potentially improve transplant accessibility for individuals with obesity and diabetes.


Subject(s)
Graft Survival , Kidney Transplantation , Pancreas Transplantation , Robotic Surgical Procedures , Humans , Kidney Transplantation/methods , Retrospective Studies , Pancreas Transplantation/methods , Male , Female , Middle Aged , Adult , Robotic Surgical Procedures/methods , Follow-Up Studies , Prognosis , Postoperative Complications , Risk Factors , Kidney Function Tests , Kidney Failure, Chronic/surgery
4.
Transplantation ; 107(9): 1903-1909, 2023 09 01.
Article in English | MEDLINE | ID: mdl-36855222

ABSTRACT

Obesity is a growing issue that is spreading worldwide; its prevalence is ever increasing in patients with end-stage renal disease and represents a potential barrier to transplantation. The lack of unanimous guidelines exacerbates the current disparity in treatment, which can affect outcomes, leading to a significantly longer time on the waiting list. Multidisciplinary and multimodal management (encompassing several healthcare professionals such as nephrologists, transplant physicians and surgeons, primary care providers, and nurses) is of paramount importance for the optimal management of this patient population in a continuum from waitlisting to transplantation. Development of this guideline followed a standardized protocol for evidence review. In this review, we report on our clinical experience in transplantation of obese patients; strategies to manage this condition, including bariatric surgery, suitable timing for transplantation among this patient population, and clinical experience in robotic sleeve gastrectomy; and simultaneous robotic kidney transplantation to achieve optimal outcomes.


Subject(s)
Bariatric Surgery , Kidney Failure, Chronic , Kidney Transplantation , Obesity, Morbid , Humans , Kidney Transplantation/adverse effects , Kidney Transplantation/methods , Obesity/complications , Obesity/diagnosis , Obesity/surgery , Bariatric Surgery/adverse effects , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/surgery , Gastrectomy/methods , Treatment Outcome
5.
Transplant Proc ; 54(8): 2344-2346, 2022 Oct.
Article in English | MEDLINE | ID: mdl-36163084

ABSTRACT

BACKGROUND: Twenty-year follow-up of the first reported simultaneous pancreas-kidney transplant from living donor between identical twins. CASE: We present a case of a patient after the world's first simultaneous pancreas and kidney transplant between identical twins. The transplant was performed because of diabetes mellitus type (DM1) related renal failure. Now in her sixties, the patient has had exceptional prolonged bi-graft function without immunosuppression. She is free from DM1 recurrence, does not take insulin, and her creatinine level has stayed with the normal limit. CONCLUSIONS: Simultaneous pancreas and kidney transplant can be performed successfully with excellent long-term outcomes.


Subject(s)
Diabetes Mellitus, Type 1 , Kidney Transplantation , Humans , Female , Kidney Transplantation/adverse effects , Twins, Monozygotic , Follow-Up Studies , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/surgery , Pancreas
SELECTION OF CITATIONS
SEARCH DETAIL
...